Cover Image
市場調查報告書

組織學檢驗及細胞診斷檢驗的北美市場展望

North America Histology And Cytology Market Outlook to 2024

出版商 GlobalData 商品編碼 346085
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
Back to Top
組織學檢驗及細胞診斷檢驗的北美市場展望 North America Histology And Cytology Market Outlook to 2024
出版日期: 2017年12月01日 內容資訊: 英文 70 Pages
簡介

本報告提供北美的組織學檢驗及細胞診斷檢驗的市場相關調查、檢測套組及試劑 (流式細胞儀、單株抗體、多株抗體、組織型判斷試劑、免疫調節劑等) 的收益規模的變化與預測、銷售處的佔有率實際成果、企業的市場佔有率實際成果、主要企業概要、開發平台、近幾年的發展趨勢等彙整資料。

第1章 目錄

第2章 簡介

第3章 北美的組織學檢驗、細胞診斷檢驗市場

  • 收益的變化與預測
  • 收益的變化與預測:各分類的比較
  • 收益:到目前為止的轉變
  • 收益:今後的預測
  • 收益的企業市場佔有率實際成果

第4章 加拿大的組織學檢驗、細胞診斷檢驗市場

  • 收益:到目前為止的轉變
  • 收益:今後的預測
  • 收益的銷售處佔有率實際成果
  • 收益的企業市場佔有率實際成果

第5章 墨西哥的組織學檢驗、細胞診斷檢驗市場

  • 收益:到目前為止的轉變
  • 收益:今後的預測
  • 收益的銷售處佔有率實際成果
  • 收益的企業市場佔有率實際成果

第6章 美國的組織學檢驗、細胞診斷檢驗市場

  • 收益:到目前為止的轉變
  • 收益:今後的預測
  • 收益的銷售處佔有率實際成果
  • 收益的企業市場佔有率實際成果

第7章 主要企業概要

  • Becton, Dickinson and Company
  • Immucor, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.

第8章 組織學檢驗、細胞診斷檢驗市場:開發中產品

第9章 近幾年的發展趨勢

  • 主要的發展趨勢
  • 策略、產業計畫

第10章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDMECR0748DB

GlobalData's new report, North America Histology And Cytology Market Outlook to 2024, provides key market data on the North America Histology And Cytology market. The report provides value, in millions of US dollars within market segments - Flow Cytometers, Immunmodulators, Monoclonal Antibodies, Polyclonal Antibodies and Tissue Typing Reagents

The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

  • Market size and company share data for Histology And Cytology market segments - Flow Cytometers, Immunmodulators, Monoclonal Antibodies, Polyclonal Antibodies and Tissue Typing Reagents
  • Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2010 to 2017 and forecast to 2024.
  • 2017 company shares and distribution shares data for each of the market segments.
  • Global corporate-level profiles of key companies operating within the North America Histology And Cytology market.
  • Key players covered include Beckman Coulter Inc, Becton Dickinson and Co and Thermo Fisher Scientific Inc.

Reasons to buy

  • Develop business strategies by identifying the key market segments poised for strong growth in the future.
  • Develop market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the market.
  • Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
  • What are the key distribution channels and what's the most preferred mode of product distribution - Identify, understand and capitalize.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 4
  • 1.2 List of Figures 4

2 Introduction 5

  • 2.1 What Is This Report About? 5
  • 2.2 Histology And Cytology Market Segmentation 5
  • 2.3 Definitions of Markets Covered in the Report 6

3 Histology And Cytology Market, North America 7

  • 3.1 Histology And Cytology Market, North America, Revenue ($m), 2010-2024 7
  • 3.2 Histology And Cytology Market, North America, Category Comparison by Revenue ($m), 2010-2024 9
  • 3.3 Histology And Cytology Market, North America, Revenue ($m), 2010-2017 11
  • 3.4 Histology And Cytology Market, North America, Revenue ($m), 2017-2024 13
  • 3.5 Histology And Cytology Market, North America, Company Share by Revenue ($m), 2017 15

4 Histology And Cytology Market, Canada 17

  • 4.1 Histology And Cytology Market, Canada, Revenue ($m), 2010-2017 17
  • 4.2 Histology And Cytology Market, Canada, Revenue ($m), 2017-2024 19
  • 4.3 Histology And Cytology Market, Canada, Distribution Share by Revenue ($m), 2017 21
  • 4.4 Histology And Cytology Market, Canada, Company Share by Revenue ($m), 2017 22

5 Histology And Cytology Market, Mexico 24

  • 5.1 Histology And Cytology Market, Mexico, Revenue ($m), 2010-2017 24
  • 5.2 Histology And Cytology Market, Mexico, Revenue ($m), 2017-2024 26
  • 5.3 Histology And Cytology Market, Mexico, Distribution Share by Revenue ($m), 2017 28
  • 5.4 Histology And Cytology Market, Mexico, Company Share by Revenue ($m), 2017 29

6 Histology And Cytology Market, United States 31

  • 6.1 Histology And Cytology Market, United States, Revenue ($m), 2010-2017 31
  • 6.2 Histology And Cytology Market, United States, Revenue ($m), 2017-2024 33
  • 6.3 Histology And Cytology Market, United States, Distribution Share by Revenue ($m), 2017 35
  • 6.4 Histology And Cytology Market, United States, Company Share by Revenue ($m), 2017 36

7 Overview of Key Companies in North America Histology And Cytology Market 38

  • 7.1 Beckman Coulter Inc 38
    • 7.1.1 Company Overview 38
  • 7.2 Becton Dickinson and Co 38
    • 7.2.1 Company Overview 38
  • 7.3 Thermo Fisher Scientific Inc 38
    • 7.3.1 Company Overview 38
  • 7.4 F. Hoffmann-La Roche Ltd 39
    • 7.4.1 Company Overview 39
  • 7.5 Immucor, Inc. 39
    • 7.5.1 Company Overview 39
  • 7.6 Sysmex Corp 39
    • 7.6.1 Company Overview 39
  • 7.7 Siemens Healthcare GmbH 39
    • 7.7.1 Company Overview 39

8 Histology And Cytology Market Pipeline Products 40

9 Recent Developments 41

  • 9.1 Corporate Communications 41
    • 9.1.1 Jul 25, 2017: Catherine Estrampes appointed President & CEO of GE Healthcare Europe 41
    • 9.1.2 Jun 23, 2017: Bellicum Announces Clinical Data on BPX-501 at Presidential Symposium of the 22nd Congress of the European Hematology Association 41
    • 9.1.3 Jun 23, 2017: Stemline Therapeutics Presents SL-401 Updated Stage 1 and 2 Data from Ongoing Pivotal Trial in BPDCN and Safety Experience Across Multiple Indications, Today at EHA 43
    • 9.1.4 Jun 12, 2017: Kieran Murphy Appointed CEO of GE Healthcare, Succeeding John Flannery 43
    • 9.1.5 Jun 05, 2017: Cortice Biosciences Announces Presentation of Final Results from the Dose Escalation Stage of a Phase 1/2 Clinical Trial Evaluating TPI 287 for Treatment of Recurrent Glioblastoma 44
    • 9.1.6 Apr 18, 2017: Biostage Appoints Stephen F. Badylak DVM, PhD, MD, as Co-Chairman of Scientific Advisory Board 46
    • 9.1.7 Mar 27, 2017: Nicolas Barthelemy and Carlos Paya Join Fluidigm Board of Directors 46
    • 9.1.8 Dec 14, 2016: Beckman Coulter appoints IT Product Manager for Northern Europe 47
    • 9.1.9 Nov 30, 2016: ARUP Laboratories appoints new CMO and director of laboratories 48
  • 9.2 Financial Announcements 48
    • 9.2.1 Nov 02, 2017: Fluidigm Announces Third Quarter Financial Results and Operational Progress 48
    • 9.2.2 Aug 14, 2017: Biostage Reports 2017 Second Quarter Financial Results 50
    • 9.2.3 Aug 03, 2017: Fluidigm Announces Second Quarter Financial Results and Operational Progress 51
    • 9.2.4 May 11, 2017: Biostage Reports 2017 First Quarter Financial Results and Provides Business Update 53
    • 9.2.5 May 04, 2017: Fluidigm Announces First Quarter Financial Results 54
    • 9.2.6 Mar 09, 2017: Biostage Reports 2016 Financial Results and Provides Business Update 56
    • 9.2.7 Feb 21, 2017: Exact Sciences reports lower Q4 net loss, provides outlook for 2017 57
    • 9.2.8 Feb 08, 2017: Fluidigm Announces Q4 And Full Year 2016 Financial Results 58
    • 9.2.9 Jan 09, 2017: Fluidigm Announces Preliminary Revenue For The Fourth Quarter And Full Year 59
    • 9.2.10 Nov 28, 2016: Toshiba Medical Launches New MR System for Efficient and Standardized Cardiac Exams 60
    • 9.2.11 Nov 10, 2016: Biostage Reports 2016 Third Quarter Financial Results and Provides Business Update 61
  • 9.3 Other Significant Developments 62
    • 9.3.1 May 18, 2017: Abcam Makes Final Performance-Based AxioMx Milestone Payment 62
  • 9.4 Product News 63
    • 9.4.1 Dec 21, 2016: Fluidigm Introduces A New Medium-Cell High-Throughput Integrated Fluidic Circuit 63

10 Appendix 64

  • 10.1 Research Methodology 65
    • 10.1.1 Coverage 65
    • 10.1.2 Secondary Research 65
    • 10.1.3 Primary Research 66
    • 10.1.4 Market Modeling and Forecasting 67
    • 10.1.5 Company Share Analysis 68
    • 10.1.6 Distribution Share Analysis 69
    • 10.1.7 Benchmarking 69
  • 10.2 GlobalData Consulting 69
  • 10.3 Contact Us 70
  • 10.4 Disclaimer 70

List of Tables

1.1 List of Tables

  • Table 1: Histology And Cytology Market, Cross Country Comparison, North America, Revenue ($m), USD Constant, 2010-2024 8
  • Table 2: Histology And Cytology Market, North America, Category Comparison by Revenue ($m), USD Constant, 2010-2024 10
  • Table 3: Histology And Cytology Market, North America, Revenue ($m), Historic, USD Constant, 2010-2017 12
  • Table 4: Histology And Cytology Market, North America, Revenue ($m), Forecast, USD Constant, 2017-2024 14
  • Table 5: Histology And Cytology Market, North America, Company Share by Revenue ($m), USD Constant, 2017 16
  • Table 6: Histology And Cytology Market, Canada, Revenue ($m), USD Constant, Historic, 2010-2017 18
  • Table 7: Histology And Cytology Market, Canada, Revenue ($m), USD Constant, Forecast, 2017-2024 20
  • Table 8: Histology And Cytology Market, Canada, Distribution Share by Revenue ($m), USD Constant, 2017 21
  • Table 9: Histology And Cytology Market, Canada, Company Share by Revenue ($m), USD Constant, 2017 23
  • Table 10: Histology And Cytology Market, Mexico, Revenue ($m), USD Constant, Historic, 2010-2017 25
  • Table 11: Histology And Cytology Market, Mexico, Revenue ($m), USD Constant, Forecast, 2017-2024 27
  • Table 12: Histology And Cytology Market, Mexico, Distribution Share by Revenue ($m), USD Constant, 2017 28
  • Table 13: Histology And Cytology Market, Mexico, Company Share by Revenue ($m), USD Constant, 2017 30
  • Table 14: Histology And Cytology Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 32
  • Table 15: Histology And Cytology Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 34
  • Table 16: Histology And Cytology Market, United States, Distribution Share by Revenue ($m), USD Constant, 2017 35
  • Table 17: Histology And Cytology Market, United States, Company Share by Revenue ($m), USD Constant, 2017 37
  • Table 18: Histology And Cytology Market Pipeline Products 40
  • Table 19: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country 67

List of Figures

1.2 List of Figures

  • Figure 1: Histology And Cytology Market, Cross Country Comparison, North America, Revenue ($m), USD Constant, 2010-2024 7
  • Figure 2: Histology And Cytology Market, North America, Category Comparison by Revenue ($m), USD Constant, 2010-2024 9
  • Figure 3: Histology And Cytology Market, North America, Revenue ($m), Historic, USD Constant, 2010-2017 11
  • Figure 4: Histology And Cytology Market, North America, Revenue ($m), Forecast, USD Constant, 2017-2024 13
  • Figure 5: Histology And Cytology Market, North America, Company Share (%) 2017 15
  • Figure 6: Histology And Cytology Market, Canada, Revenue ($m), USD Constant, Historic, 2010-2017 17
  • Figure 7: Histology And Cytology Market, Canada, Revenue ($m), USD Constant, Forecast, 2017-2024 19
  • Figure 8: Histology And Cytology Market, Canada, Company Share (%) 2017 22
  • Figure 9: Histology And Cytology Market, Mexico, Revenue ($m), USD Constant, Historic, 2010-2017 24
  • Figure 10: Histology And Cytology Market, Mexico, Revenue ($m), USD Constant, Forecast, 2017-2024 26
  • Figure 11: Histology And Cytology Market, Mexico, Company Share (%) 2017 29
  • Figure 12: Histology And Cytology Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017 31
  • Figure 13: Histology And Cytology Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024 33
  • Figure 14: Histology And Cytology Market, United States, Company Share (%) 2017 36
Back to Top